Abstract 385P
Background
Introduction: Breast Cancer is one of the most common cancer in Iranian women. Whole genome association study of breast cancer have recognized various single nucleotide polymorphisms (SNPs) that are related with increased breast cancer risk in the population. This study aimed at assessing the correlation between caspase-8 (CASP8) gene polymorphisms (rs3754934 and rs12990906) and the pathogenesis of breast cancer in Northeast of Iran.
Methods
In a case- control study a total of 450 breast cancer cases and 553 healthy subjects were included in this study. Polymorphisms were genotyped by amplification-refractory mutation system (ARMS). The chi-squared test was used to calculate Odds ratio (OR) with 95% confidence interval to determine the relationship between CASP8 polymorphisms and breast cancer risk.
Results
According to the results, after adjustment for confounding factors, rs3754934 in dominant model (CA+AA vs. CC) [p = 0.004, OR = 0.49 95% CI (0.27-0.78)] and rs12990906 in allelic model (T vs. C) [p = 0.026, OR = 1.27, 95%CI (1.03-1.58)] were associated with the risk of breast cancer in this population. We did not find any association with breast cancer risk factors, clinical and pathologic features and prognosis and considered polymorphisms.
Conclusions
Polymorphisms of CASP8 gene may have a crucial role in association with the risk of breast cancer. However, further larger studies can confirm such findings. An understanding of the mode of action of these variants will aid individual-level breast cancer risk prediction.
Clinical trial identification
Editorial acknowledgement
The authors thank all participants in this research. We would also like to thank Mashhad University of Medical Sciences and Omid hospital to support the project.
Legal entity responsible for the study
Mashhad University of Medical Sciences.
Funding
Mashhad University of Medical Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract